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Abstract
Background: The development of inhibitors against factor 8 (F8) is the most serious complication of replacement
therapy with F8 in children with severe hemophilia. It was suggested that mismatched F8 replacement therapy
may be a risk factor for the development of anti-factor F8 alloantibodies. Recently four single nucleotide
polymorphisms (SNPs) encoding six distinct haplotypes, designated H1 through H6, were studied in different
populations. Two SNPs are components of the A2 and C2 immunodominant-inhibitor epitopes.
The aim of this study is to determine the different types of haplotypes in relation with inhibitors developments
and their frequencies in our Tunisian hemophiliac population.
Materials and methods: 95/116 Tunisian patients with hemophilia A undergoing treatment at Hemophilia
Treatment Center, Aziza Othmana hospital, participate in this study. Among them only six patients develop
inhibitors. The four SNPs were amplified and sequenced.
Results and Discussion: In a total of 77 patients, we identified the H1, H2, H3 and the infrequent H5 haplotypes.
The H1 and H2 haplotypes, which have the same amino acid sequence in the recombinant F8 molecules used
clinically, are the most represented with the frequency of 0.763 and 0.157 respectively. This distribution is almost
similar to that of Caucasians in which the frequencies are respectively 0.926 and 0.074, whereas it is 0.354 and
0.374 among Subsaharians. Four patients with inhibitors studied here have the H1 haplotype. For one patient who
has a large deletion including the exon 10 we can’t identify his haplotype. Theses frequencies may explain partially
the low level of inhibitors in our patients.
Introduction
Hemophilia A is a recessively inherited X-linked bleed-
ing disorder which results from deficiency of factor VIII
(F8). Treatment consists of substitution with plasma
derived or recombinant F8 (rFVIII) [1]. F8 inhibitor is
the most serious complication of replacement therapy
with F8 in children with severe hemophilia. It remains
unclear why it concerns only proportion of patients with
hemophilia A. Several factors are reported: genetic,
environmental, immunologic, treatments type... [2]. It
was recently reported that several single-nucleotide
polymorphisms (SNPs) identified in the F8 gene may
play a role in the inhibitor development. Their incidence
differs significantly in different ethnic groups [3]. Four
non synonymous SNPs: G1679A (exon10), A2554G
(exon14), C3951G (exon14) and A6940G (exon25)
encoding respectively R484H, R776G, D1241E and
M2238V [3,4]. The R484H and M2238V are compo-
nents of the A2 and C2 immunodominant epitopes,
respectively, which have been mapped to residues
located at epitopes R484 to I508 and E2181 to V2243.
The R776G and D1241E are located in the B domain
[5,6]. The allelic combinations (haplotypes) of the four
SNPs encode six distinct wild-type F8 proteins, which
were designated H1 through H6. Two of them H1 and
H2, which have the same amino acid sequences as
respectively Kogenate
® and Recombinate
®, the recombi-
nant F8 molecules used clinically [7,8], were found in all
studied populations with a high prevalence in Cauca-
sians. The haplotypes H3, H4, and H5 were found only
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found only in Chinese people [9].
In Tunisia recombinant F8 replacement therapy was
recently introduced in 2008 for some patients. Patients
were used to be treated with plasma derived factor. In
order to identify the genetic background concerning the
SNPs and the frequency of different haplotypes of our
Tunisian hemophiliac A patients, we focused for the
first time, on the R484H, R776G, D1241E and M2238V
SNPs.
Design and methods
Patients
95 patients with hemophilia A undergoing treatment at
Hemophilia Treatment Center, Aziza Othmana Hospital
participate in this study. Each of the 95 enrolled patients
provided a blood sample. Patients or their parents gave
written informed consent for participation in this study
and the research is carried out in accordance with the
Helsinki Declaration.
PCR/sequencing
Haplotype analysis using four amplicons of genomic F8
DNA that contain respectively the R484H, R776G,
D1241E and M2238V SNPs were performed by the
polymerase chain reaction (PCR) and sequenced to gen-
otype the known non synonymous SNPs in order to
identify the different haplotypes which characterize our
Tunisian hemophiliac A patients. Haplotypes were con-
structed as a simple combination of the patient’sn o n
synonymous SNP alleles as a result for the FVIII
hemizygoty.
Result and discussion
The number of all identified Tunisian hemophiliacs A is
219 (Table 1) and 116 (53%) of them are treated in the
Hemophilia Treatment Center of Aziza Othmana Hospi-
tal [10]. Among whom 95 were enrolled in the present
study. Their age ranged between 2 and 51 years and
they have been classified into three groups according to
disease presentation 65 severe (68.48%), 26 moderate
(27.36%) and 4 mild (4.21%).
F8 haplotypes were established by sequencing four
amplicons obtained from each 95 hemophiliac patients
genomic DNA. We identified the H1, H2, H3 and the
infrequent H5 haplotypes in our patients, the two others
haplotypes H4 and H6 characteristic respectively of Sub-
saharian and Chinese populations are absent in our
hemophiliac patients. One patient was excluded from
the association analyses, since he could not be classified
within either haplotype group because he has a lager
deletion including the exon 10. After checking that
related patients share the same haplotype, we exclude
18 patients who have a familial background and we
selected only one patient from each family.
Hence we retained only 77 unrelated patients who
were classified into 58 patients with H1 haplotype, 12
patients with H2 haplotype, 5 patients with H3 haplo-
type and 1 patient with H5 haplotype (Figure 1).
The H1 haplotype is the most frequent in our sample
with a frequency of 0.763. This frequency is close to
that described for Caucasian (0.926) and Chinese (0.846)
populations and higher than that found in Subsaharian
populations (0.354).
The H2 haplotype is present in our population with a
frequency of 0.157 that is intermediate between that
observed in Subsaharian populations (0.374) and that
observed in Caucasian populations (0.074) and Chinese
(0.077).
For the H3 and H5 haplotypes, which are present in
African populations [11] and absent in Caucasian and
C h i n e s ep o p u l a t i o n s ,w ef o u n dt h es a m ef r e q u e n c yf o r
H5 (0.013) and a lesser frequency (0.065) between our
studied sample and Subsaharian populations. Our results
as compared with other ethnic groups showed an inter-
mediate position of the Tunisian sample between Cau-
casian and Subsaharian populations (Figure 2). This
result is in agreement with previous studies indicating
that Tunisian population is issued from a mixture with
Eurasian and Subsaharian contributions [11,12].
Nowadays, inhibitor development in patients with
severe hemophilia is a major complication in patient
care because they render classical substitution therapy
ineffective. F8 inhibitors occur at a frequency of 20-30%
in severe hemophilia A and 3% in hemophilia B, respec-
tively [2]. Several studies s u g g e s tt h a tp r e d i s p o s i n g
genetic factors, environmental factors and their interac-
tions contribute to the inhibitor phenotype [13].
Only 7 patients with inhibitors were identified in the
Hemophilia Treatment Center of Aziza Othmana
Hospital.
If disease severity is related with the deleterious muta-
tions in F8 gene responsible for hemophilia (gene dele-
tion, truncated protein), inhibitor production depends
Table 1 The Tunisian hemophilia A incidence in
comparison to that of other Mediterranean countries
according the World Federation of Hemophilia Report on
the ANNUAL GLOBAL SURVEY 2007
Country Haemophilia A Incidence Number of inhabitants
Tunisia 219 10,383,577
Algeria 962 33,769,669
Egypt 3365 81,713,517
France 3618 64,057,790
Italy 2697 58,145,321
Greece 739 10,722,816
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Figure 1 Haplotype frequencies of factor VIII gene identified in Tunisian hemophiliac A.
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Figure 2 Comparison of haplotype frequencies between Tunisian hemophiliac and others ethnic groups.
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F8 used for therapy is function of its structural differ-
ences with autologous F8.
The polymorphisms studied here will play a role in
t h ei n h i b i t o r sd e v e l o p m e n ts i n c et h e ya r el o c a l i z e di n
regions recognized with inhibitors (domains A2 and C2)
and will give an account for clinical data, since the inhi-
bitors development frequency is higher in some ethnic
groups [14,15].
The nature of the product used for therapy (cryopre-
cipity, rFVIII) and the time of exposure seem to influ-
ence allo immunization [15].
In conclusion, we were able to study the haplotypes
for 4 polymorphic sites linked to F8 gene, to provide the
basic information and better genetic characterization of
Tunisian hemophiliac population. Meanwhile, determi-
nation of F8 gene haplotypes might be important to
avoid or limit inhibitor production. Since study of F8
gene polymorphisms in the Africa is scarce, our results
m a yb eu s e f u lf o rS N P ss t u d i e so fF 8g e n eo fh e m o p h i -
liac A in other neighboring countries, particularly in
North Africa.
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